7.1.5	  Summary of evidence and guidelines for neoadjuvant therapy,
Recommendations,Strength rating
"If eligible for cisplatin-based chemotherapy, offer neoadjuvant cisplatin-based combination   chemotherapy to patients with muscle-invasive bladder cancer (T2-T4a, cN0 M0).",Strong
Do not offer NAC to patients who are ineligible for cisplatin-based combination chemotherapy.,Strong
Only offer neoadjuvant immunotherapy to patients within a clinical trial setting.,Strong
